Amicus Therapeutics Announces Virtual 2020 Annual Meeting of Shareholders
May 08 2020 - 7:00AM
Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated
biotechnology company focused on discovering, developing and
delivering novel medicines for rare diseases, today announced that
its 2020 Annual Meeting of Stockholders will now be held solely via
live webcast due to the public health impact of the COVID-19
pandemic and out of an abundance of concern for the health and
well-being of our employees, stockholders and directors. As
previously announced, the 2020 Annual Meeting will be held on June
4, 2020 at 9:00 am ET.
Attending the Virtual Annual
MeetingTo attend and participate in the virtual Annual
Meeting of Stockholders, stockholders of record will need to visit
www.virtualshareholdermeeting.com/FOLD2020 and use their 16-digit
control number (the “Control Number”) received in their notice to
log in to this website. Beneficial owners of shares held in street
name will need to follow the instructions provided by the broker,
bank or other nominee that holds their shares. Only one stockholder
per Control Number can access the meeting. We would encourage
stockholders to log in to this website and access the webcast
before the meeting’s start time.
Asking Questions and VotingAs
described in the proxy materials for the Annual Meeting, Amicus
stockholders as of the close of business on April 13, 2020 (the
record date) are entitled to join the live virtual meeting and
shall be able to listen, vote, and submit questions remotely.
The proxy card included with the proxy materials
previously distributed on or about April 24, 2020 will not be
updated to reflect the change in location and may continue to be
used to vote your shares in connection with the Annual Meeting. The
Company encourages eligible shareholders to vote on the proposals
prior to the Annual Meeting using the instructions provided in the
proxy materials previously distributed.
Assistance with the Virtual Annual
MeetingFurther instructions on how to attend, participate
in and vote at the virtual Annual Meeting of Stockholders will be
available at www.virtualshareholdermeeting.com/FOLD2020. A support
line will also be available on the meeting website on the day of
the virtual Annual Meeting should stockholders require assistance
with logging in. Digital copies of the company’s proxy statement
and 2019 Annual Report are available at www.proxyvote.com. These
materials also are available on the Company’s website at
https://ir.amicusrx.com/annual-reports-and-proxies.
About Amicus TherapeuticsAmicus
Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated
biotechnology company focused on discovering, developing and
delivering novel high-quality medicines for people living with rare
metabolic diseases. With extraordinary patient focus, Amicus
Therapeutics is committed to advancing and expanding a robust
pipeline of cutting-edge, first- or best-in-class medicines for
rare metabolic diseases. For more information please visit the
company’s website at www.amicusrx.com, and follow on Twitter and
LinkedIn.
Forward-Looking
StatementsStatements contained herein that relate to the
Company's 2020 Annual Meeting of Stockholders are forward-looking
statements within the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Words such as “will be”,
“will”, “may” or other similar words or expressions often identify
forward-looking statements. Such statements are based on current
expectations only, and are subject to certain risks, uncertainties
and assumptions, many of which are beyond our control. Among the
factors that could cause the Company’s 2020 annual meeting
logistical arrangements to change include: general business and
economic conditions; imposition of restrictive governmental
regulations implemented to address public health concerns; or
operational delays or difficulties because of the novel coronavirus
or similar diseases, or uncertainty regarding the same. We
undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
CONTACT:
Amicus TherapeuticsAndrew FaughnanDirector,
Investor Relationsafaughnan@amicusrx.com (609) 662-3809
FOLD–G
Amicus Therapeutics (NASDAQ:FOLD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Amicus Therapeutics (NASDAQ:FOLD)
Historical Stock Chart
From Sep 2023 to Sep 2024